Company Presentation

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage that develops first-in-class antibody therapeutics. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a novel target that plays key role in the pathology of fibrosis and cancers with immune evasive properties.